Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
Go back to Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development| Beam Inc. (NASDAQ: BEAM) | Delayed: 34.16 +0.96 (2.89%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $33.20 | 52 Week High | $83.60 | |||
| Open | $33.51 | 52 Week Low | $82.96 | |||
| Day High | $34.52 | P/E | 15.25 | |||
| Day Low | $33.51 | EPS | $2.24 | |||
| Volume | 152,539 | |||||
| Beam Inc. (NASDAQ: BEAM) | Delayed: 34.16 +0.96 (2.89%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $33.20 | 52 Week High | $83.60 | |||
| Open | $33.51 | 52 Week Low | $82.96 | |||
| Day High | $34.52 | P/E | 15.25 | |||
| Day Low | $33.51 | EPS | $2.24 | |||
| Volume | 152,539 | |||||
